INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS)

CUSIP: 45828J103

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
48,324,727
Total 13F shares
2,588,459
Share change
-131,702
Total reported value
$5,099,279
Price per share
$1.97
Number of holders
21
Value change
-$255,643
Number of buys
10
Number of sells
5

Quarterly Holders Quick Answers

What is CUSIP 45828J103?
CUSIP 45828J103 identifies INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
ARMISTICE CAPITAL, LLC
13F
Company
2.3%
1,126,868
$1,983,288 31 Dec 2024
13F
SAPIENT CAPITAL LLC
13F
Company
2%
942,841
$1,659,400 31 Dec 2024
13F
VANGUARD GROUP INC
13F
Company
0.43%
208,886
$369,728 31 Dec 2024
13F
BROWN ADVISORY INC
13F
Company
0.27%
130,072
$228,927 31 Dec 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.13%
64,349
$113,912 31 Dec 2024
13F
Sigma Planning Corp
13F
Company
0.11%
54,837
$96,513 31 Dec 2024
13F
BLAIR WILLIAM & CO/IL
13F
Company
0.08%
37,805
$66,537 31 Dec 2024
13F
One Charles Private Wealth Services, LLC
13F
Company
0.07%
31,800
$55,968 31 Dec 2024
13F
BlackRock, Inc.
13F
Company
0.05%
22,252
$39,164 31 Dec 2024
13F
Mesirow Financial Investment Management, Inc.
13F
Company
0.04%
20,000
$35,200 31 Dec 2024
13F
GTS SECURITIES LLC
13F
Company
0.04%
19,030
$33,683 31 Dec 2024
13F
Bison Wealth, LLC
13F
Company
0.04%
17,420
$30,659 31 Dec 2024
13F
CITADEL ADVISORS LLC
13F
Company
0.03%
14,964
$26,486 31 Dec 2024
13F
STATE STREET CORP
13F
Company
0.03%
14,500
$25,665 31 Dec 2024
13F
Stonebridge Financial Group, LLC
13F
Company
0.02%
8,301
$14,610 31 Dec 2024
13F
UBS Group AG
13F
Company
0.01%
3,021
$5,317 31 Dec 2024
13F
Tower Research Capital LLC (TRC)
13F
Company
0.01%
2,648
$4,660 31 Dec 2024
13F
MORGAN STANLEY
13F
Company
0%
500
$880 31 Dec 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
50
$88 31 Dec 2024
13F
JPMORGAN CHASE & CO
13F
Company
0%
17
$30 31 Dec 2024
13F

Institutional Holders of INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) as of Q1 2025

As of 31 Mar 2025, INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,588,459 shares. The largest 10 holders included SAPIENT CAPITAL LLC, ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, BROWN ADVISORY INC, GEODE CAPITAL MANAGEMENT, LLC, Sigma Planning Corp, Mesirow Financial Investment Management, Inc., BLAIR WILLIAM & CO/IL, One Charles Private Wealth Services, LLC, and Sentinus, LLC. This page lists 21 institutional shareholders reporting positions in this security for the Q1 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders
20
Q1 2025 holders
21
Holder diff
1
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 Value $ Q1 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .